The depressive effects of androgen deprivation therapy in locally advanced or metastatic prostate cancer: a comparative study

Ceylan, Yasin; Günlüsoy, Bülent; Köşkderelioğlu, Aslı; Gedizlioğlu, Muhteşem; Değirmenci, Tansu

doi:10.1080/13685538.2019.1586869

Cited by 17 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, they observed an improvement in verbal fluency after 12 months of ADT 43 . Ceylan et al 46 . did observe a decline in cognitive functioning after a treatment period of 12 months compared to baseline, but this was not different from the control group.…”

Section: Resultsmentioning

confidence: 92%

See 1 more Smart Citation

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review

et al. 2021

View full text Add to dashboard Cite

The objective of this study was to review publications assessing cognitive functioning in patients with prostate cancer treated with androgen deprivation therapy. We conducted a systematic review of the literature published in PubMed, Embase, Web of Science, Cochrane Library, and PsycINFO up to February 2020. A total of 31 studies were included. Half of the studies (n = 16) demonstrated that androgen deprivation therapy in patients with prostate carcinoma did not result in a negative effect on cognitive functioning, however, still a substantial proportion of the studies (n = 11) reported a negative effect on cognitive functioning. In four studies the results were inconclusive. In the three studies using additional functional magnetic resonance imaging, no significant effect on neuropsychological tests was found, but grey matter volume, brain activity, and brain connectivity were affected. Given the substantial number of studies showing a significant negative effect of androgen deprivation therapy on cognitive functioning, clinicians should be aware of this side effect. Furthermore, future research should focus on the further examination of brain characteristics using functional magnetic resonance imaging, since these techniques might be more sensitive in detecting brain abnormalities as a result of androgen deprivation therapy.

show abstract

Section: Resultsmentioning

confidence: 92%

“…Of the 18 prospective studies, a total of eight studies reported a decline in cognitive functioning after starting ADT 42–49 . These studies observed a decline in cognitive functioning during a follow‐up period of 3 months 42,44,45 or 12 months compared to controls 43,46–49 . Alibhai et al 49 .…”

Section: Resultsmentioning

confidence: 99%

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…27,30,36,41 The Patient Health Questionnaire (PHQ-9) was employed by two studies. 40,49 Johansson et al 17,36 and Lee et al 34…”

Section: Literature Searchmentioning

confidence: 99%

Development of depression in patients using androgen deprivation therapy: A systemic review and meta‐analysis

Qazi,

Altaf,

Zafar

et al. 2024

The Prostate

View full text Add to dashboard Cite

BackgroundAndrogen deprivation therapy (ADT) is an effective treatment for advanced prostate cancer (PCa). Multiple studies have highlighted serious consequences this therapy poses to mental health, particularly depression. We aimed to review the incidence and association between ADT in men with PCa and the risk of depression.MethodsWe systematically searched multiple databases, including MEDLINE, Scopus till August 2023 for studies that compared ADT versus control for treating PCa reporting depression as outcome. Meta‐analysis was performed using random‐effects models and results presented as odds ratios (ORs) with 95% confidence interval (CI). Quality assessment of the included studies was conducted using Joanna Briggs Institute critical appraisal checklists.ResultsA total of 38 studies (17 retrospective studies, 16 prospective studies, two cross‐sectional studies and two randomized trials) with 360,650 subjects met the inclusion criteria and were included in this meta‐analysis. The estimated pooled incidence of depression among ADT patients is 209.5 (95% CI = 122.3; 312.2) per 1000 patients. There is statistically significant relationship between ADT treatment and depression (OR = 1.46, 95% CI = 1.28, 1.67; p = 0, I2 = 86.4%). The results remained consistent across various subgroups. No risk of publication bias was detected by funnel plot and Eggers's test (p > 0.05).ConclusionThere is a higher risk of depression for men receiving ADT. Further studies evaluating optimal treatments for depression in men on ADT are warranted

show abstract

“…The fact that some studies investigating the effect of ADT on cognitive function suggest a clear association [10,41,45,[49][50][51][52][53][54], while others fail to identify one [55][56][57][58][59][60][61][62], could be attributed to the diverse definitions of cognitive dysfunction, and to differences in the assessment instruments selected and to how they were applied [63]. Furthermore, differences in patient populations, such as age, education level, comorbidities, pre-existence of genetic mutations, or choice of ADT may affect the propensity for cognitive deterioration in patients treated with ADT [34,35,52,57,61].…”

Section: Drug Treatment and Other Factors Associated With Cognitive D...mentioning

confidence: 99%

Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors

et al. 2022

View full text Add to dashboard Cite

Preservation of cognitive function is an important outcome in oncology. Optimal patient management requires an understanding of cognitive effects of the disease and its treatment and an efficacious approach to assessment and management of cognitive dysfunction, including selection of treatments to minimize the risk of cognitive impairment. Awareness is increasing of the potentially detrimental effects of cancer-related cognitive dysfunction on functional independence and quality of life. Prostate cancer occurs most often in older men, who are more likely to develop cognitive dysfunction than younger individuals; this population may be particularly vulnerable to treatment-related cognitive disorders. Prompt identification of treatment-induced cognitive dysfunction is a crucial aspect of effective cancer management. We review the potential etiologies of cognitive decline in patients with prostate cancer, including the potential role of androgen receptor pathway inhibitors; commonly used tools for assessing cognitive function validated in metastatic castration-resistant prostate cancer and adopted in non-metastatic castration-resistant prostate cancer trials; and strategies for management of cognitive symptoms. Many methods are currently used to assess cognitive function. The prevalence and severity of cognitive dysfunction vary according to the instruments and criteria applied. Consensus on the definition of cognitive dysfunction and on the most appropriate approaches to quantify its extent and progression in patients treated for prostate cancer is lacking. Evidence-based guidance on the appropriate tools and time to assess cognitive function in patients with prostate cancer is required. Plain Language SummaryMen with prostate cancer are usually elderly and may have other health conditions. Old age, poor health, and some medications can all affect a person's ability to think clearly, make sound judgments, remember things, and learn new information. These mental difficulties can make it hard for people to do day-to-day tasks such as shopping or making a meal, looking after themselves, or taking medications correctly. People may also have problems with friendships and relationships. Therefore, before a man starts treatment for prostate cancer, he and his doctor must consider the likelihood that his mental ability might be affected by the treatment in order to choose the most suitable treatment option. Initially, the doctor can use short screening tests, such as asking the patient to remember and repeat numbers or words, draw objects, name things in a picture, or complete a survey. If these tests show that the patient might be having mental difficulties, he may be invited for additional tests with a specialist, called a neuropsychologist. A patient with, or at risk of, mental difficulties will be offered a care plan, which might include one or more of the following: selecting or switching treatments to avoid side effects; using memory aids; treatment for pain, difficulty sleeping, depression, or other problems that mi...

show abstract

The depressive effects of androgen deprivation therapy in locally advanced or metastatic prostate cancer: a comparative study

Cited by 17 publications

References 34 publications

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review

Development of depression in patients using androgen deprivation therapy: A systemic review and meta‐analysis

Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors

Contact Info

Product

Resources

About